Jazz Pharmaceuticals PLC Q2 2022 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Now that you've exceeded your net leverage target early, should we think of that as unlocking potentially larger business development transactions sooner than 2023?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Can you maybe just talk about the competitive dynamics you're seeing for new patients start within narcolepsy. It was a strong quarter on your part from new patient adds, it looks like. We saw a competitor was to report strong new patient adds. So can you just elaborate a little bit on the market? Is this just sort of a normal step-up post the 1Q headwinds thrown in with -- we had Omicron earlier this year? Or is there may be just a bit more of a durable interest in the branded narcolepsy space given you have 2 branded competitors after promoting agents? And maybe just any commentary on it in terms of getting in front of physicians in person.

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : So Rylaze was really strong in 2Q. Any unusual stocking in there in the quarter? Does that all reflect demand? You mentioned that docs are switching patients back earlier if they have a reaction to asparaginase. So could you expand on that dynamic? And how should we think about that run rate from here, especially if you get Monday, Wednesday, Friday dosing?

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Great. Congrats on the quarter. Bruce, I just wanted to touch back again just once more on Epidiolex. I'm just curious, just in the context of the competitive landscape with respect to developmental therapies, I'm just curious if you could comment a bit on Epidiolex, maybe longer term, just given there have been some positive developments and some setbacks amongst the landscape of late. You certainly commented on combination and cycling, but any added thoughts as that landscape even evolved would be great.